Estimation of glomerular filtration rate (eGFR) in patients with liver disease is suboptimal in the presence of renal dysfunction. We developed a model for GFR assessment in liver disease (GRAIL) before and after liver transplantation (LT). GRAIL was derived using objective variables (creatinine, blood urea nitrogen, age, gender, race, and albumin) to estimate GFR based on timing of measurement relative to LT and degree of renal dysfunction (www.bswh.md/grail). The measured GFR (mGFR) by iothalamate clearance (n = 12,122, 1985-2015) at protocol time points before/after LT was used as reference. GRAIL was compared with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD-4, MDRD-6) equations for mGFR < 30 mL/min/1.73 m2 . Prediction of development of chronic kidney disease (mGFR < 20 mL/min/1.73 m2 , initiation of chronic dialysis) and listing or receipt of kidney transplantation within 5 years was examined in internal cohort (n = 785) and external validation (n = 68,217, 2001-2015). GRAIL had less bias and was more accurate and precise as compared with CKD-EPI, MDRD-4, and MDRD-6 at time points before/after LT for low GFR. For mGFR < 30 mL/min/1.73 m2 , the median difference (eGFR-mGFR) was GRAIL: 5.24 (9.65) mL/min/1.73 m2 as compared with CKD-EPI: 8.70 (18.24) mL/min/1.73 m2 , MDRD-4: 8.82 (17.38) mL/min/1.73 m2 , and MDRD-6: 6.53 (14.42) mL/min/1.73 m2 . Before LT, GRAIL correctly classified 75% as having mGFR < 30 mL/min/1.73 m2 versus 36.1% (CKD-EPI), 36.1% (MDRD-4), and 52.8% (MDRD-6) (P < 0.01). An eGFR < 30 mL/min/1.73 m2 by GRAIL predicted development of CKD (26.9% versus 4.6% CKD-EPI, 5.9% MDRD-4, and 10.5% MDRD-6) in center data and needing kidney after LT (48.3% versus 22.0% CKD-EPI versus 23.1% MDRD-4 versus 48.3% MDRD-6, P < 0.01) in national data within 5 years after LT. Conclusion: GRAIL may serve as an alternative model to estimate GFR among patients with liver disease before and after LT at low GFR.
Estimation of glomerular filtration rate (eGFR) in patients with liver disease is suboptimal in the presence of renal dysfunction. We developed a model for GFR assessment in liver disease (GRAIL) before and after liver transplantation (LT). GRAIL was derived using objective variables (creatinine, blood ureanitrogen, age, gender, race, and albumin) to estimate GFR based on timing of measurement relative to LT and degree of renal dysfunction (www.bswh.md/grail). The measured GFR (mGFR) by iothalamate clearance (n = 12,122, 1985-2015) at protocol time points before/after LT was used as reference. GRAIL was compared with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD-4, MDRD-6) equations for mGFR < 30 mL/min/1.73 m2 . Prediction of development of chronic kidney disease (mGFR < 20 mL/min/1.73 m2 , initiation of chronic dialysis) and listing or receipt of kidney transplantation within 5 years was examined in internal cohort (n = 785) and external validation (n = 68,217, 2001-2015). GRAIL had less bias and was more accurate and precise as compared with CKD-EPI, MDRD-4, and MDRD-6 at time points before/after LT for low GFR. For mGFR < 30 mL/min/1.73 m2 , the median difference (eGFR-mGFR) was GRAIL: 5.24 (9.65) mL/min/1.73 m2 as compared with CKD-EPI: 8.70 (18.24) mL/min/1.73 m2 , MDRD-4: 8.82 (17.38) mL/min/1.73 m2 , and MDRD-6: 6.53 (14.42) mL/min/1.73 m2 . Before LT, GRAIL correctly classified 75% as having mGFR < 30 mL/min/1.73 m2 versus 36.1% (CKD-EPI), 36.1% (MDRD-4), and 52.8% (MDRD-6) (P < 0.01). An eGFR < 30 mL/min/1.73 m2 by GRAIL predicted development of CKD (26.9% versus 4.6% CKD-EPI, 5.9% MDRD-4, and 10.5% MDRD-6) in center data and needing kidney after LT (48.3% versus 22.0% CKD-EPI versus 23.1% MDRD-4 versus 48.3% MDRD-6, P < 0.01) in national data within 5 years after LT. Conclusion:GRAIL may serve as an alternative model to estimate GFR among patients with liver disease before and after LT at low GFR.
Authors: W Ray Kim; Ajitha Mannalithara; Julie K Heimbach; Patrick S Kamath; Sumeet K Asrani; Scott W Biggins; Nicholas L Wood; Sommer E Gentry; Allison J Kwong Journal: Gastroenterology Date: 2021-09-03 Impact factor: 22.682
Authors: John D Chetwood; Mark G Wells; Tatiana Tsoutsman; Carlo Pulitano; Michael D Crawford; Ken Liu; Simone I Strasser; Geoffrey W McCaughan; Avik Majumdar Journal: Transplant Direct Date: 2022-06-10
Authors: Nadim Mahmud; Sumeet K Asrani; Peter P Reese; David E Kaplan; Tamar H Taddei; Mitra K Nadim; Marina Serper Journal: Dig Dis Sci Date: 2021-03-24 Impact factor: 3.199
Authors: Deok-Gie Kim; Shin Hwang; Jong Man Kim; Je Ho Ryu; Young Kyoung You; Donglak Choi; Bong-Wan Kim; Dong-Sik Kim; Yang Won Nah; Tae-Seok Kim; Jai Young Cho; Geun Hong; Jae Do Yang; Jaryung Han; Suk-Won Suh; Kwan Woo Kim; Yun Kyung Jung; Ju Ik Moon; Jun Young Lee; Sung Hwa Kim; Jae Geun Lee; Myoung Soo Kim; Kwang-Woong Lee; Dong Jin Joo Journal: J Clin Med Date: 2022-07-20 Impact factor: 4.964
Authors: Jin Ge; Jennifer C Lai; Justin Richard Boike; Margarita German; Nathaniel Jest; Giuseppe Morelli; Erin Spengler; Adnan Said; Alexander Lee; Alexander Hristov; Archita P Desai; Shilpa Junna; Bhupesh Pokhrel; Thomas Couri; Sonali Paul; Catherine Frenette; Nathaniel Christian-Miller; Marcela Laurito; Elizabeth C Verna; Usman Rahim; Aparna Goel; Arighno Das; Stewart Pine; Dyanna Gregory; Lisa B VanWagner; Kanti Pallav Kolli Journal: Liver Transpl Date: 2021-01-02 Impact factor: 5.799
Authors: Justin Richard Boike; Nikhilesh Ray Mazumder; Kanti Pallav Kolli; Jin Ge; Margarita German; Nathaniel Jest; Giuseppe Morelli; Erin Spengler; Adnan Said; Jennifer C Lai; Archita P Desai; Thomas Couri; Sonali Paul; Catherine Frenette; Elizabeth C Verna; Usman Rahim; Aparna Goel; Dyanna Gregory; Bartley Thornburg; Lisa B VanWagner Journal: Am J Gastroenterol Date: 2021-10-01 Impact factor: 12.045